RT Journal Article
T1 CDH18 is a fetal epicardial biomarker regulating differentiation towards vascular smooth muscle cells.
A1 Junghof, Julia
A1 Kogure, Yuta
A1 Yu, Tian
A1 Verdugo-Sivianes, Eva Maria
A1 Narita, Megumi
A1 Lucena-Cacace, Antonio
A1 Yoshida, Yoshinori
K1 Cell signalling
K1 Transcriptomics
K1 Stem-cell differentiation
K1 Regenerative medicine
AB The epicardium is a mesothelial layer covering the myocardium serving as a progenitor source during cardiac development. The epicardium reactivates upon cardiac injury supporting cardiac repair and regeneration. Fine-tuned balanced signaling regulates cell plasticity and cell-fate decisions of epicardial-derived cells (EPCDs) via epicardial-to-mesenchymal transition (EMT). However, powerful tools to investigate epicardial function, including markers with pivotal roles in developmental signaling, are still lacking. Here, we recapitulated epicardiogenesis using human induced pluripotent stem cells (hiPSCs) and identified type II classical cadherin CDH18 as a biomarker defining lineage specification in human active epicardium. The loss of CDH18 led to the onset of EMT and specific differentiation towards cardiac smooth muscle cells. Furthermore, GATA4 regulated epicardial CDH18 expression. These results highlight the importance of tracing CDH18 expression in hiPSC-derived epicardial cells, providing a model for investigating epicardial function in human development and disease and enabling new possibilities for regenerative medicine.
PB Nature Publishing Group
YR 2022
FD 2022-02-02
LK http://hdl.handle.net/10668/19558
UL http://hdl.handle.net/10668/19558
LA en
NO Junghof J, Kogure Y, Yu T, Verdugo-Sivianes EM, Narita M, Lucena-Cacace A, et al. CDH18 is a fetal epicardial biomarker regulating differentiation towards vascular smooth muscle cells. NPJ Regen Med. 2022 Feb 2;7(1):14.
DS RISalud
RD Apr 10, 2025